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Previous research into Functional Neurological Disorder (FND) has shown that there are
significant barriers in providing patient-centred care. However, there has been no specific
research into whether patient experiences of care for FND meet the current standards of
care. This study aimed to investigate the types of problems experienced by FND patients,
and whether these differed to patients with multiple sclerosis (MS). FND (n = 40) and
MS patients (n = 37) were recruited from NHS tertiary neurology clinics and completed
questionnaires on their experiences of health care services. Significant differences in
experiences of care between the two patient groups were found, with FND patients
reporting significantly more problems in their diagnosis and treatment (p = 0.003),
patient-centred care (p < 0.001), relationships with healthcare professionals (p < 0.001),
and in accessing community care (p = 0.001). Limitations include a small sample size,
specificity to a single centre, and cross-sectional design. The results suggest that current
care for FND patients is not meeting expected standards for long-term neurological
conditions, highlighting the need for structured care pathways and patient-centred care.
Keywords: functional neurological disorder, conversion disorder, patient-reported experience measure, long-term
neurological conditions, patient experience, service evaluation, standards of care, NHS
INTRODUCTION
Long-term neurological conditions (LTNCs) are conditions arising from damage to or a disease
of the nervous system that confers a life-long impact to the individual (1). They are becoming
increasingly prevalent, leading to an increasing utilisation of health and social care services to
diagnose and manage these conditions (2).
Many patients with LTNCs, however, identify unmet needs and problems with care provision.
A large-scale survey of patients with LTNCs in the UK found multiple issues, including delays
in diagnosis and referral, a lack of structured care plans, and problems in accessing services or
treatments (3). These unmet needs may contribute to increased care burden and costs for patients
as they seek the use informal and community-based care instead (4–6).
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Functional neurological disorder (FND; also referred to
as conversion/psychogenic disorder) refers to the presence of
neurological symptom (e.g., seizure-like events, limb weakness,
etc.) that are involuntary, but are incongruent with symptoms
cause by neurological disease. They very commonly have a
chronic course, thus constituting a LTNC for many patients.
Symptoms of FND are the second most common reason for
referral to neurology clinics (7) and patients with FND experience
high levels of disability and emotional distress which are equal to,
or even greater than, other LTNCs (8, 9). The prognosis of FND
in general with current management is often poor (10), although
significant rates of improvement have been found depending
on the specific groups of functional symptoms. Additionally, he
quality of life of people with FND has been found to be lower
compared to other LTNCs such as Parkinson’s disease (11). This
suggests there are issues present in the way in which FND is
managed and how FND patients are supported in current health
and social care systems.
People with FND often have to be seen multiple times before
a definite diagnosis is made, causing marked delays in diagnosis
delivery and uncertainty around the diagnosis (12, 13). The
management of FND requires specialist multidisciplinary care
across many services, including both health and social care
services within community and hospital settings, and spanning
both physical and mental health providers (14, 15). This can be
challenging due to differing approaches to management from
different healthcare professionals and between services, the lack
of resources available for FND care, and there being a lack
of knowledge about FND within healthcare services (16, 17).
Further, professionals in primary care settings, such as GPs, are
often the facilitators via which specialist management can be
accessed, and thus the attitudes and ethical presumptions of
these primary care professionals can provide additional barriers
in accessing appropriate care. Negative perceptions of patients
with FND amongst a variety of healthcare professionals (18–
20) arising from a lack of knowledge about the condition and
suspicion of feigningmay also impact the extent to which patient-
centred care is provided and lead to greater stigmatisation of
these patients (21). These barriers may therefore impact on the
experience of people with FND as they navigate health systems in
order to obtain the help they need.
However, whilst the need to improve the care pathway and
patient experience for FND has been previously identified (14,
22, 23), there has been limited research into how FND patients
experience the care they receive. Whilst there has recently been
key developments in identifying the need for more patient-
reported outcome measurements (PROMs) for people with FND
and in increasing the validity of these measurements (24, 25),
there has been little development in patient-reported experience
measures (PREMs). Thus, the subjective experiences of care that
people with FND experience, and whether this experience meets
the standards of care for LTNCs as outlined in clinical guidelines
and national policies such as theNational Service Framework, has
not previously been explored.
The National Service Framework for Long Term Conditions
(NSF) is a long-term 10 year strategy developed in the UK in
order to improve the quality of care provided for patients with
LTNCs and provide coordinated, multidisciplinary, and patient-
centred care to manage these conditions (1). It sets out quality
requirements relating to the diagnosis, management, and support
for patients with LTNCs within the UK National Healthcare
Service (NHS).
In order to measure LTNC patients’ experiences of the care
they receive, Peters et al. (26) developed the patient self-report
Health and Social Care Questionnaire based on the NSF quality
standards and relevant National Institute for Health and Care
Excellence (NICE) guidelines for managing LTNCs. Their study
found significant issues in the implementation of the NSF quality
requirements in the care of three common LTNCs (multiple
sclerosis (MS), motor neurone disease, and Parkinson’s disease).
Significant differences in the types and frequency of problems in
care between the three LTNCs were also found.
To date, there have been no studies conducted to assess the
quality of the health and social care that FND patients receive
as compared to other LTNCs. By comparing FND patients with
MS patients, who are similar in demographic characteristics
(including a female preponderance, younger age of onset than
other LTNCs, and similarly high levels of disability) (7), issues
that FND patients specifically experience within the NHS can
be elucidated. These insights can be used to inform changes in
clinical practise and care pathways.
This study therefore aimed to compare the experience of
FND patients with MS patients within the NHS using the
patient-reported Health and Social Care questionnaire developed
by Peters et al. (26) in order to explore whether there were
differences in the frequency and types of problems experienced
between the two patient groups. It was predicted that FND
patients would report a higher frequency of problems in their
experience of care services than MS patients in all domains,
and that these differences would be especially marked in areas




Ethical review and approval was not required for the study
on human participants in accordance with the local legislation
and institutional requirements. Written informed consent
from the patients was not required to participate in this
study in accordance with the national legislation and the
institutional requirements.
Participants
Seventy seven participants (40 people with FND and 37 with
MS) were prospectively and sequentially recruited from a tertiary
neurology service at anNHS hospital over the course of 3months.
Patients recruited were new attendees at these tertiary clinics,
to which patients are typically referred to for refinement in
management planning, having previously received a diagnosis
and initial management elsewhere.
At their attendance to these FND and MS clinics, they were
provided with questionnaires and asked to complete them whilst
waiting for the consultation. Patients were explicitly told they
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had the right to decline completion of the questionnaire. All data
was anonymously collected and stored in compliance with the
principles of the Data Protection Act (1998). This project was
registered and approved as an audit/service evaluation with St
George’s University Hospital audit department.
Materials
Two questionnaires were used in this audit: the Experiences of
Health and Social Care Questionnaire and the 5-level EQ-5D
questionnaire (EQ-5D-5L). The Experience of Health and Social
Care Questionnaire was developed by Peters et al. (26) tomeasure
patients’ experiences of care for their LTNC as compared to the
quality standards set out by the NSF requirements and relevant
NICE guidelines.
The EQ-5D-5L is a standardised tool that measures health-
related quality of life using 5 dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression (27). It
also asks patients to provide a general health score on a scale (0
being the worst health imaginable and 100 the best) and is used
routinely within clinical practice. The EQ-5D-5L questionnaire
was used to assess self-rated quality of life in people with MS and
FND, as well as to highlight potential confounding factors.
Data Coding and Analysis
Data Coding
Responses on the Experiences of Health and Social Care
Questionnaire were recoded into binary “problem” scores, with
0 generally indicating the absence of a problem/needs being
partially or completely met, and 1 generally indicating the
presence of a problem/needs not being met. Responses of “I am
not sure” or “Not applicable” were omitted from analysis.
Items on the EQ-5D-5L questionnaire were coded in an
ordinal manner, with 0 indicating no problem, 1 indicating a
slight difficulty, 2 indicating a moderate difficulty, 3 indicating
a severe difficulty, and 4 indicating an extreme difficulty
or inability.
Summary problem scores for each domain were calculated
by summing the total of “problem” items within each domain,
which were then used to calculate a total problem score across
all domains.
Statistical Analysis
The recoded data was analysed using the statistical program
SPSS (version 26.0; IBM Corp, 2019). Where data was normally
distributed and assumptions of statistical tests were met,
independent samples t-tests and Pearson’s chi-square tests were
used to make between-groups comparisons between MS and
FND patient data. Where data violated the assumption of
parametric tests, non-parametric tests in the form of Mann-
Whitney and Fisher exact tests were used instead. A false
discovery rate correction was applied to account for multiple-
testing issues, resulting in a Benjamini-Hochberg adjusted p-
value which was used to determine if the original p-values
remained significant (28). The significance level for all main
statistical analyses was set at α = 0.05.
RESULTS
Demographic Characteristics
The median age (FND = 45; MS = 47) and the gender
proportions for each patient group (FND = 60% female and
37.5% male; MS = 62.2% female and 37.8% male) were not
significantly different.
Summary Problem Scores
Respondents with FND had significantly higher total median
problem scores (Mdn= 17.0) compared to respondents with MS
(Mdn = 9.0, p < 0.001). The median problem scores for FND
were significantly higher than for MS across the majority of the
domains (Figure 1), including diagnosis and treatment (Mdn =
4.0 for FND and Mdn = 2.0 for MS; U = 1027.0, p = 0.003),
patient-centred care (Mdn = 6.0 for FND and Mdn = 4.0 for
MS;U = 1145.5, p< 0.001), relationships with care professionals
(Mdn = 1.0 for FND and Mdn = 0.0 for MS; U = 1111.5, p <
0.001), and community care and support (Mdn = 5.5 for FND
and Mdn = 3.0 for MS; U = 1060.5, p = 0.001). The difference
in median problem scores was not significant for the hospital
care domain, although this is likely due to the limited number
of patients who had been admitted to hospital in the sample
(n= 34).
Diagnosis and Treatment
The results of the diagnosis and treatment domain are
summarised in Table 1. Respondents with FND reported waiting
significantly longer than respondents with MS for both a
specialist consultation (p < 0.001) and a definite diagnosis
(p = 0.001). They also reported significantly more than MS
respondents that they lacked information about side effects
of their prescribed medication(s) (p = 0.010). There were no
significant differences in regards to how their diagnosis was
communicated, whether a follow-up appointment was offered,
the level of information given about their condition, the use and
review of medication, and whether self-management strategies
were given. There were no significant differences in problems
reported in receiving nutritional and respiratory support, yet it
should be noted that over half of FND patients (59.5%) and 44.1%
of MS patients reported needing but not being offered nutritional
support, suggesting there was a large proportion of both FND and
MS patients whose needs were not being met in this regard.
Patient-Centred Care
The results of the patient-centred care domain are summarised in
Table 2. FND respondents reported more difficulty in accessing
health care professionals (p < 0.010) and specialist clinics
(p < 0.010). In regards to planning their care, significantly
more FND than MS respondents felt that there was a lack of
coordination between health and social care services (p < 0.010),
that they were not involved in their care decisions (p < 0.001),
and that their wishes were not taken into account (p < 0.001).
It is notable that no respondents with MS reported the latter
problem, as compared to 60% of respondents with FND. There
were similar proportions of respondents in both groups who
reported problems in regards to not seeing any healthcare
professional within the past 12 months, not having a named
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FIGURE 1 | Median problem scores for each patient group across all domains and in total. There were significant differences between the patient groups for all
domains except the hospital care domain. Error bars represent the upper and lower quartiles of the median asterisks denote a significant difference in medians
between the patient groups at the p < 0.050 level, with ** indicating significance at the p < 0.010 level and *** indicating significance at the p < 0.001 level.
healthcare professional or care coordinator to contact, not
having a formal care plan (including problems in this not being
adequately updated), and in not receiving information about
their neurological condition.
Relationships With Care Professionals
The results of the relationships with care professionals domain
are summarised in Table 3. A significantly higher proportion of
FND respondents than MS respondents felt their needs were not
understood by hospital consultants (p < 0.010), other healthcare
professionals within the hospital (p < 0.001), and their GP
(p < 0.010). They also reported significantly more that they
felt they were not treated with respect and dignity by hospital
consultants (p < 0.050), other healthcare professionals within
the hospital (p < 0.050), and their GP (p= 0.001). This contrasts
to no respondents with MS reporting feeling they were not
treated with dignity and respect by any healthcare professional
(apart from the hospital consultant). There were no significant
differences between the patient groups in their relationships
with healthcare professionals outside the hospital and
social services.
Community Care and Support
Problems reported by respondents involving aspects of their
community care and support are summarised in Table 4.
Significantly more respondents with MS reported problems
in not receiving financial support for their neurological
condition (p < 0.010). However, more FND respondents
reported that their personal finances were affected by their
neurological condition to a large extent (p < 0.001). A
higher proportion of FND patients reported not being
offered respite care, despite needing it (p < 0.010). There
were no significant differences between patient groups
in regards to accessing paid employment, occupational
support, and guidance in staying in, returning to, or
leaving employment. Likewise, there were no significant
differences found in difficulties obtaining equipment, accessing
accommodation modifications, difficulties in applying for
financial support, accessing domestic support, and accessing
private healthcare.
Information
The majority of FND patients (81.1%) indicated that they would
have liked to receive more information in relation to their
neurological condition, which was not statistically significant
from the 64.7% of MS patients who wanted more information.
Amongst the FND patients who indicated they wanted more
information, the most frequently indicated information desired
was information about FND itself (53%), treatment for FND
(50%), self-management strategies (40%), alternative therapies
(35%), and medication (30%).
EQ-5D-5L
FND patients reported significantly more problems compared to
MS patients in regards to their mobility (p = 0.028), self-care (p
= 0.007), usual activities (p = 0.003), and pain/discomfort (p <
0.001). There were no significant differences between FND and
MS patients on problems with depression/anxiety. FND patients
also had significantly lower health scores (Mdn = 47) than MS
patients (Mdn= 70).
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TABLE 1 | Patients reporting a problem regarding the diagnosis and treatment of
their neurological condition.
Patients reporting needs not met
Total MS FND
N (%) n (%) n (%) p
Diagnosis
Time from GP consultation
to specialist consultation
(> 6 months)
36 (52.2) 7 (22.6) 29 (76.3) <0.001***
Time from initial GP
consultation to definite
diagnosis (> 12 months)




11 (21.2) 3 (10.3) 8 (34.8) 0.036
Follow-up appointment
offered
15 (27.8) 6 (19.4) 9 (39.1) 0.109
All information about
neurological condition given
23 (51.1) 10 (41.7) 13 (61.9) 0.175
Medication (only patients taking medication) & Treatment
Adequate review of
medication
11 (35.5) 4 (28.6) 7 (41.2) 0.364
Sufficient information about
how to take medication
2 (6.9) 0 (0.0) 2 (13.3) 0.259
Sufficient information on
medication side effects
14 (46.7) 3 (21.4) 11 (68.8) 0.010*
Given support to develop
self-management strategies
47 (67.1) 26 (78.8) 21 (56.8) 0.050
Offered support with
nutrition where needed
37 (52.1) 15 (44.1) 22 (59.5) 0.196
Offered respiratory support
where needed
18 (25.4) 6 (17.6) 12 (32.4) 0.153
Bolded values indicate statistical significance at the level of p < 0.05.
*Indicate values that remained significant after a false discovery rate correction, with
* Indicating significance at the p < 0.050.
**Indicating significance at the p < 0.010 level.
***Indicating significance at the p <0.001 level.
MS, Multiple Sclerosis; FND, Functional Neurological Disorder.
Values written in parenthesis are percentages.
DISCUSSION
This study aimed to explore the problems that people with
FND experience in their care by using the quality requirements
outlined in the NSF and comparing them to MS patients. As
predicted, the results indicated multiple significant differences in
the experiences of care between people with FND and with MS,
with people with FND experiencing an overall higher frequency
of problems across multiple domains of care. Four main themes
of problems that were more prevalent in FND respondents were:
(1) delayed and poor communication in diagnosis and treatment;
(2) negative relationships with healthcare professionals; (3)
difficulties in accessing services and support; and (4) the burden
of poor care experienced by FND patients. Together, these results
indicate that the current care provided to FNDpatients within the
NHS is falling significantly short of the standards of care expected
for LTNCs, highlighting potential areas for improvement.
TABLE 2 | Patients reporting a problem regarding the health and social care of
their neurological condition.
Patients reporting needs not met
Total MS FND
N (%) n (%) n (%) p
Seen any healthcare
professional within the last
12 months
6 (7.8) 3 (8.1) 3 (7.5) 0.624
Experienced difficulty in
seeing healthcare
professionals in the last 12
months
48 (70.6) 17 (53.1) 31 (86.1) 0.003**
Attended a specialist clinic
with the last 12 months
37 (52.9) 11 (33.3) 26 (70.3) 0.002**
Assigned a named
healthcare professional to
contact when needs change
50 (79.4) 23 (71.9) 27 (87.1) 0.136
Assigned a single health or
social care professional who
coordinates care
50 (87.7) 23 (85.2) 27 (90.0) 0.439
Good coordination between
health and social care
services in planning care
23 (65.7) 3 (30.0) 20 (80.0) 0.008**
Existence of formal care
plan
67 (91.8) 32 (91.4) 35 (92.1) 0.623
Formal care plan is
adequately updated (for
those who have a formal
care plan)
4 (50.0) 2 (50.0) 2 (50.0) 0.757
Given information about
their condition (if visited a
consultant in the last 12
months)
23 (32.4) 9 (26.5) 14 (37.8) 0.307
Patient involved as much as
they would like in decisions
about their care
23 (47.9) 1 (5.9) 22 (71.0) <0.001***
Patient wishes and
preferences taken into
account by health and
social care professionals
18 (40.0) 0 (0.00) 18 (60.0) <0.001***
Bolded values indicate statistical significance at the level of p < 0.05.
*Indicate values that remained significant after a false discovery rate correction, with
* Indicating significance at the p < 0.050.
**Indicating significance at the p <0.010 level.
***Indicating significance at the p < 0.001 level.
MS, Multiple Sclerosis; FND, Functional Neurological Disorder.
Values written in parenthesis are percentages.
Delayed and Poor Communication in
Diagnosis and Treatment
People with FND identified marked problems in the time
taken to be referred and diagnosed, as well as problems in the
communication of treatment information. They thus experienced
more delays in referral and diagnosis, reporting more frequently
that they waited over 6 months for a specialist referral and over
12 months to receive a definite diagnosis. Additionally, they also
identified poor communication in regards to the side effects of
medications that they were prescribed for their condition. These
Frontiers in Neurology | www.frontiersin.org 5 May 2021 | Volume 12 | Article 656466
O’Keeffe et al. Patient Experiences of FND Care
TABLE 3 | Patients reporting a problem regarding their relationships with health
and social care professionals.
Patients reporting needs not met
Total MS FND
N (%) n (%) n (%) p
Perception of whether their needs are understood by
healthcare professionals
Consultants in the hospital 12 (20.7) 1 (3.7) 11 (35.5) 0.003**
Other healthcare
professionals in the hospital
13 (28.9) 0 (0.0) 13 (50.0) <0.001***




10 (32.3) 2 (15.4) 8 (44.4) 0.092
Social services 8 (34.8) 1 (25.0) 7 (36.8) 0.565
Treated with dignity and respect by healthcare professionals
Consultants in the hospital 10 (15.9) 1 (3.4) 9 (26.5) 0.013*
Other healthcare
professionals in the hospital
7 (14.0) 0 (0.0) 7 (25.0) 0.012*




6 (24.0) 0 (0.0) 6 (40.0) 0.028
Social services 4 (19.0) 0 (0.0) 4 (25.0) 0.304
Bolded values indicate statistical significance at the level of p < 0.05.
* Indicate values that remained significant after a false discovery rate correction, with *
indicating significance at the p < 0.050.
** Indicating significance at the p < 0.010 level.
*** Indicating significance at the p <0.001 level.
MS, Multiple Sclerosis; FND, Functional Neurological Disorder.
Values written in parenthesis are percentages.
delays and poor communication thus suggest that people with
FND often wait longer to receive specialist care and, when they
do access this care, they may be insufficiently informed of the
expected side effects of the treatment. This may have a significant
impact on both the outcome of their FND and their engagement
with their treatment.
Prompt diagnosis and treatment is key in FND, as well as
in LTNCs in general. Stone et al. (29) highlighted the role
of diagnosis as a therapeutic tool in itself for FND, with
symptoms often remitting or becoming less severe once a
patient understands their cause and the potential for treatment.
Consequently, delays in referral and thus delays in receiving
a definite diagnosis means that people with FND may have
to live with treatable disability for longer periods of time and
risk the severity of their symptoms worsening. Multiple studies
have shown that delayed diagnosis and a longer duration of
symptoms are indicators of poor prognosis in FND and other
functional disorders, whilst a shorter duration of symptoms,
early diagnosis, and a high satisfaction with care predict
more positive outcomes (10, 13, 30, 31). It is therefore clear
that prompt diagnosis and treatment is key to improving
outcomes for FND. Yet the FND respondents in this sample
experienced significant delays, suggesting that there are issues
TABLE 4 | Patients reporting a problem regarding aspects of community care and
support.
Patients reporting needs not met
Total MS FND
N (%) n (%) n (%) p
Have not been in paid
employment within the last
3 years
29 (42.0) 9 (27.3) 20 (55.6) 0.017
Assessment of how their
neurological condition
affects their work
15 (38.5) 7 (30.4) 8 (50.0) 0.217
Occupational therapist
liaised with employer
10 (27.8) 7 (35.0) 3 (18.8) 0.242
Guidance to stay in
employment
13 (32.5) 5 (20.8) 8 (50.0) 0.054
Guidance to leave
employment
13 (33.3) 7 (30.4) 6 (37.5) 0.645
Guidance to return to
employment




23 (76.7) 8 (80.0) 15 (75.0) 0.571
Access to modifications to
accommodation for their
neurological condition
17 (34.7) 5 (22.7) 12 (44.4) 0.112
Receipt of financial support
for modifications to
accommodation
3 (15.0) 0 (0.0) 3 (15.8) 0.850
Receipt of financial support
for their neurological
condition
14 (21.9) 11 (36.7) 3 (8.8) 0.007**
Ease of applying for financial
support
38 (86.4) 10 (76.9) 28 (90.3) 0.235
Personal finances affected
by neurological condition
34 (48.6) 9 (25.7) 25 (71.4) <0.001***
Offered help with
housework
20 (29.0) 7 (20.6) 13 (37.1) 0.130
Offered help with personal
care
5 (6.8) 1 (2.8) 4 (10.8) 0.187




11 (15.1) 5 (13.9) 6 (16.2) 0.781
Bolded values indicate statistical significance at the level of p < 0.05.
*Indicate values that remained significant after a false discovery rate correction, with
* indicating significance at the p < 0.050.
**Indicating significance at the p < 0.010 level.
***Indicating significance at the p < 0.001 level.
MS, Multiple Sclerosis; FND, Functional Neurological Disorder.
Values written in parenthesis are percentages.
within the referral and diagnosis pathway for FND which have
the potential to negatively impact the long-term outcomes of
their condition.
Additionally, the EQ-5D-5L demonstrates that these delays
are not due to people with FND presenting with lower levels of
disability, as they indicate that people with FND actually report
significantly higher levels of disability across the majority of
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domains for health-related quality of life and have an overall
worse health score. This corroborates previous findings that FND
patients experience high levels of disability that equal or exceed
that of other LTNCs (8, 9). Although these levels of disability
are self-reported, it highlights that these patients are subjectively
experiencing significant impairments within their daily lives,
indicating a need for care, and support. Therefore, regardless of
whether the severity of these disabilities are objectively different
in the eyes of healthcare professionals, there should still be
support offered to these patients to manage the impact that their
disability has on their daily life.
Poor communication of medication side effects has been
shown to be a problem within both physical and mental
health contexts (32, 33), and has both ethical and practical
implications for informed consent and the risk of adverse
effects (34). More people with FND than with MS reported
receiving inadequate information about the side effects of their
prescribed medications, suggesting that these patients were
potentially not able to make a fully informed decision about
their-medical care and did not experience the same standard
of communication from their healthcare providers that people
with MS did. This is perhaps explained by the lack of evidence-
based medication available across the spectrum of FNDs (35) and
healthcare professionals’ general lack of confidence and training
in FND (36–38).
Poor Relationships With Healthcare
Professionals
People with FND also reported significantly more problems in
their relationships with healthcare professionals. A substantial
proportion of people with FND reported that they felt that
their GP, consultant, and other healthcare professionals within
the hospital neither understood their needs nor treated them
with respect, something which only a few people with MS
reported. This likely is linked to a significant lack of patient-
centred care that these results also highlighted, as they also
reported that they did not feel involved in their treatment
decisions and felt that their wishes and preferences about
managing their FND were not considered. Thus, a lack of
patient-centred care for people with FND may have negative
consequences on the relationships between these patients and
healthcare professionals.
Issues with implementing patient-centred care, a vital
component in improving patient outcomes (39, 40), may be in
part explained by the stigma and negative perceptions attached
to the FND diagnosis. For example, consultants have previously
reported that they found people with FND more difficult to treat
and support (41). Additionally, multiple studies have identified
negative perceptions of FND in various healthcare professionals,
including neurologists, psychiatrists, GPs, and nurses (18, 42–
44). Lehn et al. (38) survey of healthcare practitioners linked
these negative perceptions to a fundamental lack of knowledge
or misunderstanding of what FND is. This is likely due to the
precise aetiology of FND still remaining uncertain, although
more recent research has begun to highlight the role of
interacting psychological and physiological mechanisms (45, 46).
Multiple studies have shown that people with FND report
feeling stigmatised by healthcare professionals (47) and have
had negative experiences during their care as a result, including
feeling ignored, blamed, or humiliated in their interactions
with professionals (21, 48). Patients in Lehn et al. (38) study
attributed these negative experiences to healthcare professionals
invalidating their experience and removing their autonomy
over care decisions, which have also been echoed in the
current results.
These results thereby suggest a need to develop more
patient-centred care that removes stigmatising and negative
experiences in the care of FND patients. Simple education
for all healthcare professionals involved in the care of FND
patients may be a beneficial and cost-effective step toward
decreasing the stigma and negative perceptions attached to
FND. For example, Lehn et al. (49) found that a brief
educational course for healthcare professionals, created through
multidisciplinary collaboration, was effective in improving the
knowledge and confidence of professionals in assessing and
supporting patients with FND, with this effect still present at 6
months follow up. Further, Rosendal et al. (50) developed an
educational programme to educate GPs about the assessment
and management of functional disorders in general and
found that the programme decreased GP’s negative attitudes
toward functional patients and increased their satisfaction
with interacting with these patients. Educating professionals
may thus improve the relationships between patients and
healthcare professionals.
Difficulties Accessing Services and
Support
Significant difficulties were experienced by people with FND
in accessing services and support. They reported significant
problems with the accessibility of healthcare professionals and
specialist clinics, with a majority reporting that they had not been
to a specialist clinic within the past year. They also highlighted
issues in accessing respite care despite feeling they needed it.
These difficulties may relate to the negative attitudes toward FND
which may limit the responsiveness of healthcare professionals to
the needs of these patients. For example, Ahern et al. (44) found
that a substantial minority of neurology nurses with negative
perceptions of people with FND symptoms also thought that
they did not deserve the same level of care as patients with
organic symptoms and were less willing to spend time caring
for them. Although these were self-reported attitudes, there is an
implication that these attitudes may actually translate into less
responsive care for FND patients.
The difficulties in accessing services and healthcare
professionals may also reflect problems in the structure
and coordination of care services for FND and LTNCs in general,
as a significant proportion of people with FND reported a lack
of coordination between services in planning their care. Jackson
et al. (51) found that people with LTNCs viewed coordination
between services as vital in ensuring that there is a continuity of
care within community settings, but that they often experienced
limited access to these services. Since FND is often managed
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within community settings and requires multidisciplinary
treatment (14), it is thus vital to have coordination between
different services which should include, for many patients, a
coordination between community neurotherapy and community
mental health services.
Burden of Illness
The consequences of the difficulties experienced by people
with FND in these results is demonstrated through the burden
of illness they also experience. The majority of people with
FND in our sample felt that their personal finances were
affected by their neurological condition to a large extent, despite
them actually reporting significantly less problems in receiving
financial support. The reason for this apparent paradox is
unclear, although it is perhaps due to people with FND being
unaware that they are able to access financial support, and/or
that they often rely more on their own finances for their care
due to a lack of confidence in public health and social care
services. Sowińska and Czachowski (52), for example, found that
people with functional symptoms in often have low expectations
of their conditions being treated by healthcare professionals
within public services, and instead sought treatment from
private healthcare practitioners. As Stone (53) points out, some
people with functional symptomsmay disengage from healthcare
services due to the stigma and lack of support they experience,
suggesting that these patients may thus have to rely on informal
methods of care, potentially having a negative impact on their
personal finances to a larger extent than other LTNCs. Thus,
people with FNDmay experience a greater burden (both financial
and emotional) from their condition as a result of stigma and
structural service issues.
The burden of care was also illustrated by the majority of
people with FND (81.1%) desiring more information about their
condition. Although this was not significantly different from
MS patients, it suggests that most people with FND within our
sample felt that they lacked information about their condition,
with the most frequently desired categories of information being
information about FND, treatment for FND, self-management
strategies, alternative therapies, and medications available for
FND. Since these patients do not feel adequately educated
about these topics regarding FND by health and social care
professionals, it is thus up to the patient to seek out information
from other sources, increasing the burden on these patients
and making them vulnerable to potential misinformation. This
thereby emphasises the need for patient-centred care and
educational resources for these patients.
LIMITATIONS
There are important limitations to this study that may restrict
the generalisability of the results. The relatively small sample size
(N = 77) and that fact that the audit was only conducted at a
single hospital means that replicating these findings in a larger
sample across multiple neurology services would be important
in validating the results of this current study. It would also be
useful in identifying whether these problems are present across
all neurology services or if specific characteristics of services,
including management approach and level of specialism, may
influence the frequency and type of problems reported. This
would be important in elucidating the contextual factors that
cause the problems reported in this study, thus providing more
specific recommendations for service improvement. The patients
in this study also only responded at one time point, and thus
it is unclear how their experiences may have changed after
contact with tertiary neurology services and over longer periods
of time. This is particularly relevant as the patients presenting
to the clinics in this study were referred primarily for further
management planning of their condition. Thus, exploring the
ways in which reported problems change after contact with
neurology services may provide a more longitudinal view of
FND patients’ experiences throughout their contact with varying
NHS services, from more general primary care services to more
specialist neurology services. Further, more control groups are
needed using a wider range of psychiatric and neurological
conditions, as well as other types of functional disorders, to parse
out the specific difficulties experienced by people with FND.
CONCLUSIONS
These results suggest that negative attitudes and perceptions of
FND from healthcare professionals, along with a general lack of
structured care pathways for FND, may contribute to a greater
burden and poorer experience of care for these patients. There
are significant issues in the care of FND patients that require
an integrated, systematic approach to address and mitigate
these problems.
This may require the implementation of a stratified care
model, as proposed by Healthcare Improvement Scotland
(22), wherein there is a clear care pathway that directs
health professionals and patients toward appropriate treatment
depending upon need. Although specialist FND clinics remain
rare, Aybek et al. (54) found them to have an important
role in delivering accurate diagnoses and ensuring patients
had access to appropriate care, and patients were found
to be responsive to integrated neuropsychiatric management.
Thus, the development of specialist multi-disciplinary FND
clinics has the promise of improving both access to care and
patient experiences. Gilmour et al. (14) noted that improving
the knowledge and skills of community-based healthcare
professionals and primary care workers is a vital step in
developing effective, interdisciplinary stepped-care pathways for
FND, which further highlights the role of education in improving
care for FND patients. NHS England (55) has emphasised the
importance of involving patients in the development of care
pathways, suggesting there is also a need for both more research
into FND patients’ experiences of healthcare and the use of
patient steering groups in order to deliver genuine patient-
centred care.
The development of FND-specific care pathways that utilise
interdisciplinary working, patient-centred care, and a stratified-
care approach may therefore have significant potential in
improving the experience of people with FND within the
care services.
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